HomeProductsBioactive CompoundsEpigeneticsHistone MethyltransferaseTazemetostat
Chemical structure of CAS 1403254-99-8

Tazemetostat

CAS No.1403254-99-8
MDL No.N/A
MFC34H44N4O4
MW572.70
InChI KeyNSQSAUGJQHDYNO-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma that cannot be completely resected.

CAS No.1403254-99-8
Product NameTazemetostat
Heavy Atom Count42Rotatable Bond Count9
Atom Stereo Count0Bond Stereo Count0
HBA6HBD2
TPSA86.900 ŲCharge0
Exact Mass572.33626Complexity1437.13
pKa5.875XLogP4.735

Related Articles

Studies related to this compound and its mechanism of action

Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF by synergistically decreasing global trimethylation of H3K27.

Journal of cellular and molecular medicine • Vol. 24, Issue 6 • 2020
PMID: 31970877PMC: PMC7131946DOI: 10.1111/jcmm.15007

Loss of Expression of a Novel Chromatin Remodeler SMARCA1 in Soft Tissue Sarcoma.

Journal of cytology & histology • Vol. 9, Issue 6 • 2018
PMID: 31093468PMC: PMC6513346DOI: 10.4172/2157-7099.1000524

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

The Lancet. Oncology • Vol. 19, Issue 5 • 2018
PMID: 29650362DOI: 10.1016/S1470-2045(18)30145-1

Targeting EZH2 with tazemetostat.

The Lancet. Oncology • Vol. 19, Issue 5 • 2018
PMID: 29650364DOI: 10.1016/S1470-2045(18)30149-9

Documentation

Similar Products